Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
- 12 July 2011
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 163 (7), 1344-1364
- https://doi.org/10.1111/j.1476-5381.2011.01238.x
Abstract
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL(-1) . They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. http://dx.doi.org/10.1111/bph.2011.163.issue-7.Keywords
This publication has 165 references indexed in Scilit:
- Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ9-tetrahydrocannabinolDrug and Alcohol Dependence, 2010
- Chemical profile, antifungal, antiaflatoxigenic and antioxidant activity of Citrus maxima Burm. and Citrus sinensis (L.) Osbeck essential oils and their cyclic monoterpene, dl-limoneneFood and Chemical Toxicology, 2010
- Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the BedsideNeurotherapeutics, 2009
- Orphan endogenous lipids and orphan GPCRs: A good matchProstaglandins & Other Lipid Mediators, 2009
- Human Cannabinoid PharmacokineticsChemistry & Biodiversity, 2007
- Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and gliaNeuroscience Letters, 2006
- Effects of the essential oil from Citrus aurantium L. in experimental anxiety models in miceLife Sciences, 2006
- Anti-Platelet Aggregation and Chemical Constituents from the Rhizome ofGynura japonicaPlanta Medica, 2003
- LimoneneJournal of Applied Toxicology, 1995
- Neurobehavioral actions of cannabichromene and interactions with Δ9-tetrahydrocannabinolGeneral Pharmacology: The Vascular System, 1983